who should not take glp-1 receptor agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways MYTH BUSTER #1 “Weight-loss injections
Description
20 in the journal Nature Medicine
Public interest in, and use of, GLP-1 and GLP-1/GIP medications for weight loss is growing rapidly
Censani M, Chin VL, Fennoy I
2.1 Given these gaps, we propose the following recommendations based on current evidence 2.1.1 For clinicians We propose a clinical medication use management process that encompasses review, screening, combination therapy, education, monitoring, and follow-up (Table 3)
Furthermore, this patient subgroup reported increased adverse events related to weight loss (ROR = 10.85, 95% CI 9.1212.91) and metabolic disturbances
